Comvita hits 5-yr high on early results from diabetes trial

Shares of Comvita rose 2.7 percent to a five-year high of $3.80 after a company statement detailed the results of medical research, yet to be peer-reviewed, showing its olive leaf extract boosts the effectiveness of insulin in overweight, middle-aged men at risk of diabetes.

Undertaken by the Liggins Institute, a medical research centre of at the University of Auckland, the research examined "a range of complex health outcomes, including insulin responses among those trial participants who took fresh olive leaf extract for 12 weeks."

The research project concluded that the fresh olive leaf extract "improves the way insulin is secreted and works in overweight men," the company said in a statement to the NZX.

The research has been submitted to an unnamed "highly prestigious, international medical journal".

Detailed comment on the research is prohibited by the requirements of the peer review process, which the research must pass to be published.

Using 45 overweight men with an average age of 46.6, the trial found taking the extract "was associated with a 15 percent improvement in insulin action, and a 28 percent improvement in insulin secretion."

It found no significant changes in other areas tested, including "lipid profile, ambulatory blood pressure, body composition, carotid intimal thickness, or parameters of liver function."

Comvita last year saw off a takeover bid from Cerebos Greggs, a global food manufacturer, pitched at $2.50 a share, which was rejected by directors, who put a value range of $3.40 and $4 a share.

BusinessDesk

Comments from our readers

No comments yet

Add your comment:

Your name:
Your email:	Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Anti-spam verification:

Type the text you see in the image into the field below. You are asked to do this in order to verify that this enquiry is not being performed by an automated process.

Related News:

Comvita may not increase earnings in 2014 as higher honey prices bite, Craigs says
Comvita turned to a loss in first half, remains confident of increasing annual profit
Nasdaq-listed Derma Sciences takes 7.3 percent stake in Comvita in discounted placement
Comvita FY profit falls 10 percent , beating guidance, on honey shortage, rising costs
Comvita flags 15 percent fall in FY profit as expensive honey, supply shortages prompt downgrade
Comvita buys Aussie groves to expand olive extract output
Comvita first-half earnings fall 7.4% amid short supply
Comvita buys Whanganui-based Kiwi Honey for undisclosed sum
Comvita to seek deeper pool for directors' fees at AGM
Comvita's net profit surges to a record, dividend jumps